Declining Stock and Solid Fundamentals: Is The Market Wrong About HBM Holdings Limited (HKG:2142)?
It is hard to get excited after looking at HBM Holdings' (HKG:2142) recent performance, when its stock has declined 17% over the past three months. However, stock prices are usually driven by a company’s financial performance over the long term, which in this case looks quite promising. Specifically, we decided to study HBM Holdings' ROE in this article.
Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.
How Is ROE Calculated?
The formula for return on equity is:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
So, based on the above formula, the ROE for HBM Holdings is:
26% = US$74m ÷ US$284m (Based on the trailing twelve months to June 2025).
The 'return' is the profit over the last twelve months. That means that for every HK$1 worth of shareholders' equity, the company generated HK$0.26 in profit.
Check out our latest analysis for HBM Holdings
What Has ROE Got To Do With Earnings Growth?
Thus far, we have learned that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.
HBM Holdings' Earnings Growth And 26% ROE
First thing first, we like that HBM Holdings has an impressive ROE. Second, a comparison with the average ROE reported by the industry of 7.9% also doesn't go unnoticed by us. Under the circumstances, HBM Holdings' considerable five year net income growth of 55% was to be expected.
As a next step, we compared HBM Holdings' net income growth with the industry and found that the company has a similar growth figure when compared with the industry average growth rate of 48% in the same period.
Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. If you're wondering about HBM Holdings''s valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.
Is HBM Holdings Using Its Retained Earnings Effectively?
HBM Holdings doesn't pay any regular dividends to its shareholders, meaning that the company has been reinvesting all of its profits into the business. This is likely what's driving the high earnings growth number discussed above.
Summary
Overall, we are quite pleased with HBM Holdings' performance. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. Having said that, on studying current analyst estimates, we were concerned to see that while the company has grown its earnings in the past, analysts expect its earnings to shrink in the future. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.
The New Payments ETF Is Live on NASDAQ:
Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.
Explore how this launch could reshape portfolios
Sponsored ContentValuation is complex, but we're here to simplify it.
Discover if HBM Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:2142
HBM Holdings
A biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally.
Flawless balance sheet with solid track record.
Market Insights
Weekly Picks
THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

The Quiet Giant That Became AI’s Power Grid
Recently Updated Narratives

A case for USD $14.81 per share based on book value. Be warned, this is a micro-cap dependent on a single mine.
Occidental Petroleum to Become Fairly Priced at $68.29 According to Future Projections
Agfa-Gevaert is a digital and materials turnaround opportunity, with growth potential in ZIRFON, but carrying legacy risks.
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)
